Form 4: Elutia Inc. Executive Michelle LeRoux Williams Reports Stock Transactions Following RSU Vesting

Michelle LeRoux Williams, Chief Scientific Officer of Elutia Inc., reports the acquisition and disposal of Class A Common Stock related to the vesting of restricted stock units (RSUs).

Summary

• On August 12, 2024, Michelle LeRoux Williams, Chief Scientific Officer of Elutia Inc., reported transactions involving the company's Class A Common Stock.
• These transactions are related to the vesting of 50,000 restricted stock units (RSUs) granted on January 31, 2024.
• Upon vesting, Williams received 50,000 shares of Class A Common Stock.
• 15,800 shares were withheld by Elutia Inc. to satisfy tax withholding requirements at a price of $2.84 per share.
• Following these transactions, Williams directly owns 51,300 shares of Elutia Inc. Class A Common Stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The vesting of RSUs is a positive event, indicating the achievement of a milestone (FDA clearance). The filing itself is a routine disclosure.

Positives

• The vesting of RSUs indicates that performance milestones related to the FDA clearance of EluPro have been achieved.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership. It reflects the impact of regulatory milestones (FDA clearance) on executive equity awards.

Stakeholder Impact

• Shareholders may view the vesting of RSUs as a positive sign, indicating progress and achievement of company goals.
• Employees may be motivated by the vesting of RSUs, as it aligns their interests with those of the company.

Key Dates